Open AccessActivity of Posaconazole Combined with Amphotericin B against Aspergillus flavus Infection in Mice: Comparative Studies in Two Laboratories
Author(s) -
Laura K. Najvar,
Anthony Cacciapuoti,
Steve Hernandez,
Judith Halpern,
Rosie Bocanegra,
Maya Gurnani,
Frederick Menzel,
David Loebenberg,
John R. Graybill
Publication year - 2004
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.48.3.758-764.2004
Subject(s) - posaconazole , amphotericin b , aspergillus flavus , aspergillosis , pharmacology , antagonism , in vivo , aspergillus fumigatus , biology , aspergillus , microbiology and biotechnology , medicine , immunology , antifungal , receptor
Posaconazole and/or amphotericin B was given to mice pretreated with a steroid and then infected by inhalation of Aspergillus flavus conidia. Two laboratories conducted studies using almost identical protocols to evaluate both survival and lung tissue burdens 8 days after infection. The results of the in vivo studies performed at both laboratories were consistent. We found that (i). up to 5 mg of amphotericin B per kg of body weight was poorly effective in treating invasive aspergillosis; (ii). posaconazole at 2 or 10 mg/kg/dose prolonged survival and reduced lung tissue CFU; and (iii). there was generally no antagonistic interaction of the drugs in combination, even when the experiments were designed to maximize the likelihood of antagonism. These studies do not confirm the antagonistic interaction of triazoles and polyenes reported by others.